CMV reactivation under foscarnet prophylaxis in cord blood transplantation: Increased NRM without impact on relapse or survival (ASH 2025) - Dec 5, 2025 - "Prophylactic administration of letermovir was not performed. Tacrolimus and mycophenolate mofetil were used for GVHD prophylaxis... In CBT with early post-transplant prophylactic administration of FOS, CMV reactivation was associated with increased NRM, although no significant impact on relapse or OS was observed. CMV disease had a substantial negative impact on NRM and OS, underscoring the importance of timely intervention."
Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Nephrology • Pneumonia • Respiratory Diseases • Transplantation
|
|
Shogo Matsui 1; Hisashi Yamamoto 1; Mika Kuno 1; Otoya Watanabe 1; Kyosuke Yamaguchi 2; Kosei Kageyama 2; Daisuke Kaji 1,3; Yuki Taya 2,3; Aya Nishida 1; Kazuya Ishiwata 2; Shinsuke Takagi 1,4,5; Yuki Asano-Mori 3,5; Go Yamamoto 1; Atsushi Wake 2,4,5; Shuichi Taniguchi 1; Naoyuki Uchida 1,4
|